Unity Biotechnology upgraded by Wedbush with a new price target
$UBX
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $8.00 | Buy | Rodman & Renshaw |
| 11/16/2023 | $2.00 → $4.00 | Neutral → Outperform | Wedbush |
| 1/4/2022 | $4.00 | Neutral → Buy | Roth Capital |
| 1/4/2022 | Neutral → Buy | ROTH Capital | |
| 11/10/2021 | $5.00 → $7.00 | Neutral → Buy | Mizuho |
| 6/28/2021 | Sell → Buy | Citigroup | |
| 6/28/2021 | $6.00 | Sell → Buy | Citigroup |
10-K/A - Unity Biotechnology, Inc. (0001463361) (Filer)
8-K - Unity Biotechnology, Inc. (0001463361) (Filer)
144 - Unity Biotechnology, Inc. (0001463361) (Subject)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
4 - Unity Biotechnology, Inc. (0001463361) (Issuer)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
SC 13G/A - Unity Biotechnology, Inc. (0001463361) (Subject)
Rodman & Renshaw initiated coverage of Unity Biotechnology with a rating of Buy and set a new price target of $8.00
Wedbush upgraded Unity Biotechnology from Neutral to Outperform and set a new price target of $4.00 from $2.00 previously
Roth Capital upgraded Unity Biotechnology from Neutral to Buy and set a new price target of $4.00
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals. "Dr. Grossi's extensive experience in clinical strategy and a successful track record of advancing novel ophthalmolo
SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company's corporate and product strategies. "Alicia's impressive experience in ophthalmology product planning, commercial strategy, and scaling cross-functional teams will be instrumental in fortifying our strategies and capitalizing on the significant opportunity of UBX1325 to transform the treatment landscape for diabetic macular edema (DME)," said Anirvan Ghosh, Ph.
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here. The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management to review 24- and 36-week results from the Phase 2b ASPIRE study evaluating the safety and efficacy of UBX1325 in patients with DME. UBX1325 is a potent BCL-xL inhibitor that acts via a senolytic mec
SAN FRANCISCO, March 10, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that Yehia Hashad, M.D., executive vice president of research and development and chief medical officer at Bausch + Lomb, has been appointed to the Company's board of directors and as a member of its science committee. "Dr. Hashad is a highly respected leader in ophthalmology whose expertise will be invaluable as we prepare for the upcoming Phase 2b ASPIRE 24-week data readout and optimize our strategy to potentially advance UBX1325 to late-stage development," said Anirvan Ghosh, Ph.
Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% confidence interval), but did not meet statistical non-inferiority on the average of weeks 20 and 24, the primary analysis endpoint (met at 88% confidence interval) UBX1325-treated patients had a +5.2 letter gain in visual acuity at 24 weeks and a +5.5 letter gain at 36 weeks UBX1325 was numerically superior to aflibercept at 7 out of 10 time points in a pre-specified population with moderately aggressive disease UNITY to host investor call with retinal expert Robert B. Bhisi
A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injections through 48 weeks Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the duration of the study UBX1325 had a favorable safety and tolerability profile with no evidence of intraocular inflammation UNITY to host investor call with retinal expert Robert B. Bhisitkul, M.D., Ph.D., today, April 24 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., April
UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline 52% of UBX1325-treated patients did not require anti-VEGF treatment through 24 weeks Company to share 48-week BEHOLD DME data in April and intends to initiate Phase 2b study in DME in second half of 2023 UNITY to host investor call today, March 27, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company d